drugset / Trial / NCT04878211
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study evaluated if relapsing multiple sclerosis (MS) participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once monthly could develop an adequate immune response to the COVID-19 mRNA vaccine compared to participants on an interferon or glatiramer acetate.
Timeline
- Start
- 2021-06-10
- Primary completion
- 2023-04-14
- Completion
- 2023-04-14
Outcome
Outcome not reported
Stopped (Business): “Trial was terminated for business reasons. There has been no change in the benefit/risk profile of ofatumumab.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COVID-19 mRNA vaccine | Vaccine | — | — |
| Subject | Glatiramer Acetate | Small molecule | — | — |
| Subject | Interferon | Unknown | — | — |
| Subject | Ofatumumab | Monoclonal antibody | 20 mg | Subcutaneous |